top of page

BTAI U.S. Patent Issues on Use of BXCL 701 (talabostat)

  • Writer: BPIQ
    BPIQ
  • Feb 5, 2023
  • 2 min read

BTAI is in a challenging situation with respect to BXCL 701 (talabostat), the oncology asset now at the heart of its immuno-oncology subsidiary, Onkosxcel because talabostat is a prior art compound not discovered by Onkosxcel or BTAI (FIG. 1).

Want to read more?

Subscribe to bpiq.com to keep reading this exclusive post.

 
 
 
bottom of page